Business
Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference
Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference ...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMeta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nMeta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference\nCanada NewsWire\nWINNIPEG, Feb. 23, 2016\n\n\n\nComparison of High-Dose Bolus Tirofiban With Other Anticoagulants in 41 Clinical Studies Involving 38,645 Patients Selected as iMPACT Trial\n\n\n\nWINNIPEG, Feb. 23, 2016 /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that a study titled \"Comparison of High-Dose Bolus Tirofiban With Other Anticoagulation Strategies for Percutaneous Coronary Intervention: A Network Meta-Analysis of Randomized Controlled Trials\" was presented by primary investigator and lead author, Dr. Michael J. Lipinski, M.D., Ph.D., of the MedStar Heart and Vascular Institute in Washington, DC at the Cardiovascular Research Technologies (CRT) 2016 conference.\n\nThe CRT conference, which concludes today at the Omni Shoreham Hotel in Washington, DC, is one of the leading educational forums on new cardiovascular technology and procedures for physicians and health care professionals. \n\nThe study was selected as a late-breaking iMPACT Trial at the CRT conference. iMPACT Trials are those studies selected to be innovative and providing the latest breakthroughs in clinical science, and are expected to highlight new improvements in quality of patient care and significantly \"iMPACT\" the field of interventional cardiology.\n\nThe investigators pooled data from 41 randomized clinical trials to perform a network meta-analysis to directly and indirectly compare different glycoprotein IIb/IIIa inhibitor (GPI) strategies for percutaneous coronary intervention with a focus on the impact of High-Dose Bolus (HDB) tirofiban.  A total of 38,645 patients were included in the analysis (2,654 randomized to HDB tirofiban, 6,752 to abciximab, 1,669 to eptifibatide, 16,500 to heparin, and 11,070 to bivalirudin).  Results of the ...